Doxycyclin

Phase 3Small molecule

TTanta University

Doxycyclin is one of 75 small molecule programs targeting Granuloma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GranulomaActive, not recruiting

Breast CancerActive, not recruiting

COVID-19Active, not recruiting

GranulomaPreclinical

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Tykerb

GSK

Preclinical

80 3

Doxycyclin

TTanta University

Phase 3

1 4

Adriamycin

GGynecologic Oncology Group

Preclinical

87 5

Prolia

Amgen

Preclinical

14 6

Gemzar

GGynecologic Oncology Group

Preclinical

22 7

Megace

Bristol-Myers Squibb

Preclinical

4 8

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 9

Blenoxane

Bristol-Myers Squibb

Preclinical

1 10

Chantix

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2/3Recruiting

CLE

NCT05972772

Q2 2028

Phase 2/3Not yet recruiting

Combination Therapy

NCT05897034

Q4 2028

Phase 2Recruiting

Breast Cancer

NCT06452394

Clinical

Trials by Indication[1]

Breast Cancer1 trial

NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline

Recruiting·SSwiss Cancer Institute·Phase 2·NCT06452394·50 enrolled

Combination Therapy1 trial

Combination Therapy Between Doxycycline, Pentoxifylline, and Nitazoxanide in Sexually Active Men

Not yet recruiting·TTanta University·Phase 2/3·NCT05897034·100 enrolled

CLE1 trial

Rickettsia Clearance Study

Recruiting·—·Phase 2/3·NCT05972772·72 enrolled

Diabetes1 trial

Doxycycline in Type II Diabetes

Recruiting·MMostafa Bahaa·Phase 1/2·NCT06329882·60 enrolled

Meibomian Gland Dysfunction1 trial

Comparison Between Continuous and Pulsed Oral Doxycycline Treatment Protocols for Refractory Meibomian Gland Dysfunction

Completed·UUniversity of Milan··NCT06520007·65 enrolled

5 more indications

Prevention1 trial

Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya

Completed·UUniversity of Washington·Phase 4·NCT06582966·60 enrolled

Azithromycin1 trial

Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea

Completed·—·Phase 4·NCT06090565·161 enrolled

COVID-191 trial

OD-doxy-PNV-COVID-19 Old Drug " DOXY " for Prevention of New Virus " COVID-19 "

Completed·HHedi Gharsallah·Phase 3·NCT04584567·194 enrolled

Granuloma1 trial

Comparison Of Doxycycline And Common Salt For Treatment Of Umbilical Granuloma: A Randomised Control Trial

Completed·SShaheed Zulfiqar Ali Bhutto Medical University·N/A·NCT05545462·196 enrolled

Unspecified1 trial

A Two Week Nitazoxanidebased Quadruple Regimen

Unknown status·TTanta University·Phase 3·NCT02621359·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Doxycyclin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Doxycyclin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Doxycyclin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tanta University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTanta University

Doxycyclin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2028

Q4 2028

Trials by Indication[1]

Breast Cancer1 trial

Combination Therapy1 trial

CLE1 trial

Diabetes1 trial

Meibomian Gland Dysfunction1 trial

Prevention1 trial

Azithromycin1 trial

COVID-191 trial

Granuloma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News